26 results about "White adipose tissue" patented technology

Provided is a novel Lactobacillus fermentum strain (Accession No. KCTC 14106BP) and a composition for preventing or treating a metabolic disease including the same. A Lactobacillus fermentum according to the present invention may inhibit fat accumulation and increase anti-inflammatory cells in white adipose tissue. In addition, the Lactobacillus fermentum may effectively inhibit fat accumulation in brown adipose tissue and in liver tissue. The Lactobacillus fermentum strain may exhibit excellent blood glucose improvement effect, and in particular, may reduce a fasting blood glucose level. The Lactobacillus fermentum strain may effectively ameliorate insulin resistance by improving glucose tolerance and increasing insulin sensitivity. Therefore, the Lactobacillus fermentum strain may be usefully used to prevent or treat a metabolic disease such as obesity.

Provided is a Bifidobacterium bifidum strain, Bifidobacterium bifidum ibiome001, which can significantly reduce body weight gain and white adipose tissue weight gain of high fat diet-induced obese and diabetic mice, and enhances expression of lipolytic genes ATGL and HSL. Moreover, Bifidobacterium bifidum ibiome001 can significantly lower fasting blood glucose levels, area under curves (AUCs) of the oral glucose tolerance (OGTT) curve, plasma glycated hemoglobin levels and insulin levels of diabetic mice. It is suggested that Bifidobacterium bifidum ibiome001 is a promising potential probiotic strain for the treatment of metabolic syndrome such as obesity, diabetes and the like, which is more effective than other Bifidobacterium strains / compositions.

Provided is a polynucleotide including a nucleotide sequence encoding a vestigial like 4 protein and a cis-regulatory element that controls hepatocyte-specific expression of the sequence encoding a vestigial like 4 protein. Also provided is a viral vector including the polynucleotide, and a cell or organism transfected by the polynucleotide. Also provided is a method of treating steatohepatitis, obesity, hyperglycemia, diabetes, insulin resistance, liver inflammation, or decreasing white adipose tissue in the subject. Also provided is a method of screening a treatment for fatty liver disease or prevention of cirrhosis, comprising feeding a diet high in fat, fructose, and / or cholesterol to a transgenic animal having an hepatocyte-specific vestigial like protein gene disruption, administering the treatment to the transgenic animal, and detecting a difference in liver morphology or liver function between the transgenic animal and a control animal.

The invention relates to application of DOP (dioctyl phthalate) in preparation of medicines for regulating lipid metabolism, resisting diabetes and resisting intestinal microorganisms. The DOP significantly alleviates DIO by inhibiting the expansion of lipid droplets (LD) in white adipose tissue (WAT) and down-regulating LD-related genes (including PLIN2 and PLIN3). DOP can target visceral fat, significantly improve visceral fat hypertrophy and hyperplasia (especially epididymal fat EAT is taken as aboriginal) induced by high fat diet (HFD), inhibit formation of lipid droplets, reduce expression of lipid droplet coating protein PLIN2 / 3, and block the accumulation process of lipid droplets (LD). Consistent with we have observed that DOP also inhibits the expression of genes associated with lipid synthesis and adipogenesis, including Fabp1, Fast, Ldlr, Cebpb, and Dio2. These findings show that DOP can improve diet-induced obesity by regulating lipid droplet-related pathways.

The present application relates to the application of delta-Viniferin in the preparation of drugs for preventing or treating metabolic cardiovascular diseases. Delta-Viniferin can inhibit the expression level of aging and inflammation related genes / proteins of vascular endothelial cells, reduce endothelial dysfunction, and clarify its anti-hypertensive effect. Delta-Viniferin can inhibit the expression level of vascular smooth muscle cell phenotype conversion related genes / proteins, improve the contraction function of vascular smooth muscle, and significantly alleviate the degradation of elastic fibers of the vascular wall and the rupture of the intima of the aortic wall in vivo, and clarify its effect on preventing and treating aortic dissection. Delta-Viniferin can inhibit the expression level of myocardial fibroblast fibrosis related genes / proteins, and clarify its anti-myocardial fibrosis effect. Delta-Viniferin can promote white adipose tissue browning by targeting the SIRT1-FOXO1 axis, increase energy consumption, and clarify its effect on resisting obesity. In summary, the compound delta-Viniferin has the effect of protecting various metabolic cardiovascular diseases, and can be used to prepare drugs for preventing and treating metabolic cardiovascular diseases.

The application relates to the technical field of new application of a targeted drug, in particular to application of plitidepsin in preparation of a medicine for treating obesity and improving sugar metabolism. It is known that plitidepsin can reduce the body weight, fat content, and inguinal white adipose tissue and epididymal white adipose tissue content of a treatment object, and can improve the sugar tolerance and insulin sensitivity of the treatment object. Therefore, plitidepsin can be used for preparing a medicine for treating obesity and improving sugar metabolism.

The invention relates to the technical field of biological medicine, in particular to a compound and a preparation method thereof, a photo-thermal agent and application of the photo-thermal agent in obesity treatment. The compound has a structure as shown in a formula I in the specification, wherein R is selected from at least one of anthracene-containing groups, dibenzothiophene-containing groups or carbazole-containing groups, and X is selected from at least one of halogen atoms, PF6 <-> and BF4 <->. The compound provided by the invention has mitochondrial targeting property and good photothermal conversion capability, and can realize obesity treatment by promoting the browning process of white adipose tissues.

The invention discloses a fruit and vegetable fiber capable of improving GLP1 in vivo, which is prepared by the following steps: soaking peels of citrus fruits with hot water, removing white pulp layers, washing with water, and draining; grinding the fruit peels, inoculating aspergillus niger and plant lactobacillus, fermenting and sterilizing to obtain fermented fruit and vegetable fibers; performing ultrasonic treatment, adding water, adding xylanase and cellulase, performing enzymolysis, and performing enzyme deactivation to obtain enzymolysis fruit and vegetable fiber liquid; homogenizing, passing through an ultrafiltration membrane, intercepting filtrate, and spray-drying to obtain insoluble fibers; collecting permeate liquid, passing through a nanofiltration membrane, intercepting filtrate, and freeze-drying to obtain soluble fibers; and compounding the insoluble fiber part and the soluble fiber part to obtain the fruit and vegetable fiber. The invention further discloses application of the fruit and vegetable fibers in sugar control and weight reduction. The traditional Chinese medicine composition can effectively enhance satiety, inhibit excessive accumulation of white adipose tissues, activate a heat production function of brown adipose tissues, regulate body fat balance, activate a GLP-1 signal channel, inhibit appetite center and improve glycolipid metabolism.

The present invention relates to a composition for preventing or treating metabolic dysfunction-associated liver disease comprising oenotein B, wherein oenotein B reduced elevated liver-related parameters in an animal model of metabolic dysfunction-associated steatotic liver disease, reduced body weight, liver weight, and white adipose tissue to alleviate liver steatosis, reduced inflammation, and inhibited liver fibrosis. Therefore, the composition has the effect of being able to be effectively used for preventing or treating metabolic dysfunction-associated liver disease including liver steatosis, metabolic dysfunction steatohepatitis, and liver fibrosis.

The invention discloses an application of Pantoea ananatis, and relates to the technical field of microorganisms. Aiming at the defects of the existing obesity intervention means, the invention provides a brand-new solution: Pantoea anatitis adapted to a high-altitude environment is used as a core functional strain, through an intestinal flora driving mechanism, the expression of UCP1 protein in brown adipose tissue (BAT) is activated, the heat production function of the BAT is enhanced, and meanwhile, the storage of white adipose tissue (WAT) and the level of liver triglyceride (TG) are reduced; the weight-losing effect is realized. The strain can play a role through an'intestinal flora-BAT 'axis without cold exposure, has no obvious influence on liver functions, and is excellent in safety. The invention discloses a flora-mediated non-cold-dependent BAT activation way for the first time, can be used for preparing products such as weight-reducing medicines and health-care foods, has the advantages of mechanism innovation, exact effect and wide application, and provides a new technical choice for obesity intervention.

This invention discloses the application of a Dickkopf-related protein 3 regulator in the preparation of metabolic regulation products. This invention is the first to propose and verify the novel functions of exogenous Dickkopf-related protein 3 in the regulation of adipose thermogenesis and the regulation of energy metabolism homeostasis in the body. It clarifies that it can promote lipid decomposition in adipocytes, enhance the thermogenic activity of adipocytes, promote the browning of white adipose tissue, and exert its effects through a non-UCP1-dependent pathway that promotes the stability of SERCA2b protein. This provides a new target and technical means for the intervention of lipid metabolism disorders such as obesity, type 2 diabetes, metabolic syndrome, and non-alcoholic fatty liver disease.

The application provides a method for regulating lipid absorption, a composition and application thereof. The present inventors have been committed to the research on the correlation between diet and metabolism, and found in the previous research that compared with before diet restriction, re-feeding after diet restriction can significantly increase the body fat content. Further research shows that the composition of intestinal flora during normal diet after diet restriction changes significantly, and the proportion of lactobacillus increases significantly; high-protein diet after diet restriction can significantly inhibit the increase of the proportion of small intestinal lactobacillus, and the diversity of flora is significantly increased. Clearing the intestinal flora can effectively inhibit the increase of body fat caused by re-feeding after diet restriction. The present inventors have also found that a five-compound combination of a specific lactobacillus strain can significantly increase lipid absorption and fatty acid uptake of white adipose tissue.

The invention discloses bifidobacterium adolescentis and application of the bifidobacterium adolescentis in fat reduction. The bifidobacterium adolescentis is preserved in the China General Microbiological Culture Collection Center, and the preservation number is CGMCC (China General Microbiological Culture Collection Center) No.31381. The bifidobacterium adolescentis has the effects of reducing the body fat rate, reducing weight, inhibiting the body weight rebound after weight loss, maintaining the weight loss effect, improving the blood fat and the like, promotes brown fat to produce heat and promotes white fat to be converted into brown fat, and meanwhile has high safety superior to that of weight-reducing drugs. In addition, when the medicine or food is used for treating and preventing obesity, the total cholesterol and total triglyceride levels are reduced, the liver function is improved, the pancreas health is maintained, the fat cell area is reduced, liver fat infiltration is reduced, the intestinal flora is regulated, and the inflammation level is reduced.

In the body, adipose tissue is comprised of adipocytes as well as various other cell types, including immune cells, that may contribute to the overall extracellular vesicle pool. Adiponectin, a protein hormone produced by fat cells, and fatty acid binding protein 4 (FABP4) were selected as markers to isolate adipocyte- specific EVs / adipomes from the total pool of white adipose tissue-derived EVs based on in vitro data showing that they colocalized with Annexin V, an apoptosis marker, on the surface of budding apoptotic bodies. Intact L-adipomes (large- adipomes) and S-adipomes (small-adipomes) were successfully and selectively enriched from large-EVs and small-EVs, respectively. Immunoblotting analysis confirmed the presence of adiponectin, FABP4, Annexin V, and perilipin in both L- and S-adipomes, providing further evidence of their adipocyte origin.

This invention provides an aptamer targeting the growth hormone receptor and its uses, the nucleotide sequence of which is shown in SEQ ID NO.1 or SEQ ID NO.2. This invention utilizes a modified SELEX technique to perform multiple rounds of screening targeting recombinant GHR protein, obtaining specific nucleic acid aptamers with high affinity for GHR (KD values ​​at the micromolar level). In vivo distribution experiments show that the fluorescently labeled aptamer can efficiently and specifically accumulate in white adipose tissue (including inguinal and gonadal fat) at the in vivo level, exhibiting excellent tissue targeting. The nucleic acid aptamer and its derivatives of this invention can be used to prepare drugs or diagnostic reagents targeting adipose tissue, for example, for the prevention or treatment of metabolic diseases such as obesity, type 2 diabetes, fatty liver, hyperlipidemia, or cardiovascular disease.

This invention discloses a tsRNA molecule associated with the browning of white adipose tissue and its applications. This invention provides a potential therapeutic target for the prevention and / or treatment of obesity and related metabolic diseases.

The invention relates to the technical field of health-care functional food, in particular to novel application of a composition. The composition provided by the invention is prepared from the following raw materials in parts by weight: 120 parts of lotus leaves, 30 parts of haws and 80 parts of mulberry leaves. The raw materials are mainly selected from medicinal and edible food materials and part of common nutritional food materials which are all natural plant raw materials. The applicant deeply studies the characteristics of the raw materials, carries out comprehensive and systematic in-vivo and in-vitro experimental verification respectively by screening and blending various food raw materials according to the two characteristics of preventing and reducing obesity of the product, and finally determines the composition of the optimized variety of the raw materials. The invention also relates to an application of the functional health-care food for preventing and reducing obesity and synchronously protecting intestinal barriers and liver tissues, and the functional health-care food is used for preventing and reducing obesity by inhibiting the whitening of brown fat, promoting the browning of white fat and enhancing the heat energy conversion of body lipid after being taken.

In the body, adipose tissue is comprised of adipocytes as well as various other cell types, including immune cells, that may contribute to the overall extracellular vesicle pool. Adiponectin, a protein hormone produced by fat cells, and fatty acid binding protein 4 (FABP4) were selected as markers to isolate adipocyte-specific EVs / adipomes from the total pool of white adipose tissue-derived EVs based on in vitro data showing that they colocalized with Annexin V, an apoptosis marker, on the surface of budding apoptotic bodies. Intact L-adipomes (large-adipomes) and S-adipomes (small-adipomes) were successfully and selectively enriched from large-EVs and small-EVs, respectively. Immunoblotting analysis confirmed the presence of adiponectin, FABP4, Annexin V, and perilipin in both L- and S-adipomes, providing further evidence of their adipocyte origin.

The invention belongs to the technical field of medicines, and particularly relates to a composition and application thereof in preparation of a medicine for treating osteoporosis-sarcopenia-obesity triple symptoms. The invention provides a composition. The composition contains sanggenone C, morusin, sanggenone D, phellinus linteus ketone G and morusin. The composition can synchronously regulate and control bone, muscle and fat tissues; osteoclast differentiation is inhibited, and osteogenesis is promoted; the muscle strength and endurance are enhanced, and the quality of gastrocnemius muscle and soleus muscle is improved; visceral fat is reduced, white fat browning is promoted, and fat reduction without muscle reduction is achieved. Compared with an existing single-target medicine, the composition has the advantages that the muscle function and fat metabolism are remarkably improved while the bone mineral density is improved, and the limitation of single treatment of a single disease is overcome. The composition is derived from plants, is high in safety, has a synergistic effect when being combined with glucosamine chondroitin calcium tablets, and has good clinical transformation and application prospects.

The invention belongs to the technical field of medicines, particularly relates to the crossing field of development of natural active ingredients and prevention and treatment of metabolic diseases, and particularly relates to application of Rk1 in preparation of medicines or functional foods for relieving diseases caused by high fat diet. The ginsenoside Rk1 disclosed by the invention is proved to be orally taken, so that rapid weight increase of mice and excessive white fat expansion caused by high-fat diet can be remarkably reduced, and the lipid content in serum can be reduced; meanwhile, insulin resistance can be effectively relieved, adipose tissue inflammatory response is relieved, and intestinal endotoxemia is prevented by protecting the integrity of the colon barrier. The ginsenoside Rk1 has the potential of serving as a natural therapeutic agent for relieving the diseases caused by the high-fat diet, and a new thought is provided for developing medicines or functional foods for assisting in preventing and treating the diseases caused by the high-fat diet.

The invention relates to application of circular RNA (Ribonucleic Acid) to preparation of nucleic acid drugs. Experimental research proves that the circular RNA circPde5a can be used for preparing the long-acting weight-losing and blood-sugar-reducing nucleic acid medicine; after circPde5a is delivered to target tissues (such as pancreas islet tissues and white adipose tissues), the dual effects of losing weight and reducing blood sugar can be realized by regulating and controlling related pathways of metabolism of the target tissues. Meanwhile, the circPde5a can be used in cooperation with an existing treatment means.

The invention belongs to the cross technical field of biological medicine and neuropsychiatric medicine, and particularly relates to application of an SAA1 protein inhibitor in preparation of a medicine for treating methylamphetamine addiction withdrawal syndrome. The invention reveals that the mesenteric white adipose tissue plays a key role in anxiety, depression and other negative emotions induced by withdrawal of methylamphetamine by secreting SAA1 protein for the first time, and further obviously increases the drug foraging behavior and relapse risk. By inhibiting or reducing SAA1 protein expression or activity from mesenteric white fat, negative emotion related to withdrawal can be effectively relieved, so that psychological desire and relapse rate are reduced. The invention provides an inhibitor taking SAA1 protein as a target spot, an antibody, a gene silencing tool or application thereof. The inhibitor, the antibody and the gene silencing tool are used for preparing drugs or preparations for treating methylamphetamine addiction withdrawal syndrome and preventing relapse. The target and the treatment method provide a brand new way and strategy for material use disorder, especially clinical intervention of methamphetamine dependence.

A method for directing a change in cell state of white adipose tissue (WAT) which involve treating WAT cells with mRNA encapsulated inside lipid nanoparticles (LNPs). The mRNA encodes UCP1 or other proteins that may transition WAT to brown adipose tissue (BAT). The LNP may contain (C14-4:NCL:Cholesterol:PEG / Lipid Conjugate) at the molar ratio of (35:16:46.5:2.5), (50:10:38.5:1.5) or (56.5:10:31.8:1.7).

The present invention provides novel methods for promoting recruitment and activation of brown adipose tissues (BAT) or arousing browning of white adipose tissues (WAT) in a mammal, comprising administration to the mammal a composition comprising an effective amount of dihydroberberine or a pharmaceutically acceptable salt, acid, ester, polymer, analog or derivative thereof. The present invention also provides a composition comprising an effective amount of dihydroberberine or a pharmaceutically acceptable salt, acid, ester, polymer, analog or derivative thereof, for promoting recruitment and activation of brown adipose tissues (BAT) or arousing browning of white adipose tissues (WAT) in a mammal.

A method for directing a change in cell state of white adipose tissue (WAT) which involve treating WAT cells with mRNA encapsulated inside of a lipid nanoparticle (LNP). The mRNA encodes a sequence for synthesizing UCP1 or other proteins that may transition adipose tissue from WAT to brown adipose tissue (BAT). The LNP may contain (C14-4: NCL: Cholesterol: PEG / Lipid Conjugate) at the molar ratio of (35: 16: 46.5: 2.5), (50: 10: 38.5: 1.5) or (56.5: 10:31.8: 1.7).

The application discloses application of sodium humate in preparation of a medicine for treating obesity, and relates to the technical field of biological medicine. The application finds that the sodium humate has the effect of treating obesity, and further combined with near-infrared photothermal treatment can effectively improve the treatment effect on obesity. It is detected that the sodium humate has excellent photothermal conversion performance and good photothermal stability, and this characteristic lays a key foundation for the sodium humate in combination with the near-infrared photothermal treatment of obesity. Experiments prove that the sodium humate can realize efficient photothermal conversion in the fat area, and provides a precise action mode for local fat intervention. Animal experiments prove that the sodium humate and the sodium humate combined with photothermal treatment can effectively reduce the degree of obesity. Meanwhile, the combined treatment can improve the distribution of adipose tissue, realize remodeling of the adipose phenotype, and especially can promote the browning of white adipose tissue.